Enhanced post-licensure safety surveillance of a new recombinant acellular pertussis vaccine licensed as a monovalent (aP, Pertagen®) and tetanus, reduced-dose diphtheria combinati...

by Librada Fortuna, Surasith Chaithongwongwatthana, Ngamphol Soonthornworasiri, Jane Spiegel, Wassana Wijagkanalan, Souad Mansouri, Anita H.J. van den Biggelaar, Hong Thai Pham
Published 2020

Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial

by Geraldine Blanchard Rohner, Olga Chatzis, Pailinrut Chinwangso, Marie Rohr, Stéphane Grillet, Carole Salomon, Barbara Lemaître, Pitchaya Boonrak, Saranath Lawpoolsri, Elizabeth Clutterbuck, Indrajeet Kumar Poredi, Wassana Wijagkanalan, Jane Spiegel, Hong Thai Pham, Simonetta Viviani, Claire Anne Siegrist
Published 2020

Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aP<inf>gen</inf> or combined TdaP<inf>gen</inf> vaccines

by Punnee Pitisuttithum, Jittima Dhitavat, Chukiat Sirivichayakul, Arom Pitisuthitham, Yupa Sabmee, Pailinrut Chinwangso, Chawanee Kerdsomboon, Librada Fortuna, Jane Spiegel, Mukesh Chauhan, Indrajeet Kumar Poredi, Anita H.J. van den Biggelaar, Wassana Wijagkanalan, Simonetta Viviani, Souad Mansouri, Hong Thai Pham
Published 2022